RFG
VRTX icon

REAP Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

REAP Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$82.2K Buy
184
+2
+1% +$933 0.02% 231
2025
Q4 		$82.5K Buy
182
+29
+19% +$12.5K 0.02% 233
2025
Q3 		$59.9K Buy
153
+16
+12% +$6.69K 0.01% 244
2025
Q2 		$61K Buy
137
+77
+128% +$35.5K 0.01% 243
2025
Q1 		$29.1K Buy
60
+28
+88% +$13K 0.01% 270
2024
Q4 		$12.9K Buy
32
+1
+3% +$464 ﹤0.01% 339
2024
Q3 		$14.4K Hold
31
– – ﹤0.01% 312
2024
Q2 		$14.5K Sell
31
-3
-9% -$1.3K ﹤0.01% 283
2024
Q1 		$14.2K Buy
+34
New +$14.4K ﹤0.01% 330

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

REAP Financial Group's VRTX Position: Q1 2026 in Review

REAP Financial Group increased its Vertex Pharmaceuticals (VRTX) stake by 1.1% in Q1 2026, buying an estimated $933 and bringing the position to 184 shares worth $82.2K. The position accounts for 0.02% of the portfolio, ranked #231.

REAP Financial Group first reported a position in VRTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $82.5K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • REAP Financial Group held 184 shares of Vertex Pharmaceuticals worth $82.2K as of Q1 2026.
  • REAP Financial Group bought 2 Vertex Pharmaceuticals shares in Q1 2026, an estimated $933.
  • Vertex Pharmaceuticals made up 0.02% of REAP Financial Group's portfolio in Q1 2026, its #231 holding.
  • REAP Financial Group first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • REAP Financial Group's Vertex Pharmaceuticals position peaked at $82.5K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on REAP Financial Group's 13F filing for Q1 2026, filed 11 May 2026.